
|
 |
Policy Review
Nonpharmaceutical Interventions
for Pandemic Influenza, International Measures
World Health Organization Writing Group*1
|
Appendix. Presymptomatic or asymptomatic
influenza viral shedding and relationship of shedding with symptoms,
as determined in representative studies
|
|
|
First author
|
Nature of study
|
Pertinent results
|
Pertinent conclusions
|
|
|
Frank (1)
|
Surveillance in families, Houston, Texas, 1975–1979
|
In a study of 50 influenza A illnesses in 41 children
<4 years of age, presymptomatic viral shedding was noted in 4
(8%) from whom positive samples were obtained 6, 4, 3, and 3 days,
respectively, before symptom onset. Samples were not cultured for
most children before symptom onset. Peak shedding occurred during
week 1 of illness, when 73% of cultures were positive; 10% were
positive on days 8–11, 5% on days 12–15, and 0% days 16–19. Illness
duration and shedding were not correlated.
|
In children, at least 8% of illnesses in a seasonal
outbreak were associated with presymptomatic shedding, which was
noted up to 6 days before illness; 5% continued to shed at the end
of week 2. Peak rates of shedding correlated with symptoms.
|
| |
|
Hall (2)
|
Children with respiratory illness seeking medical
care during influenza outbreaks, Rochester,
New York, 1977 and 1986
|
In an influenza B study of 43 children (mean age
8 y), 74% had typical influenzalike illness, 7% had afebrile upper
respiratory infections, and 19% had croup. Peak virus titers occurred
on day 1 of illness, and 93% of children shed virus on days 1–3,
75% on day 4, and 30% on day 6. Severe illness and prolonged fever
were associated with higher virus titers, and a trend (p<0.07)
for younger children to shed higher-titer virus occurred. In an
influenza A study, symptoms and the highest viral shedding occurred
early in illness; 30% of patients still shed at day 7.
|
Peak shedding early in illness, correlated with
symptoms and fever.
|
| |
|
Davis
(3)
|
Surveillance in families, Washington,
DC area, 1951–1956
|
Influenza A virus was recovered from 0/4 and 2/3
throat swab samples obtained 3–5 and 1–2 days, respectively, before
symptoms, compared with 75 (59%) of 127 swab specimens collected
within 3 days after onset of illness.
|
Shedding at low levels occurred 1–2 days before
symptoms
|
| |
|
Foy (4)
|
Surveillance in families, Seattle,
Washington, 1984
|
12/37 persons, all >12 y of age, from whom influenza
B virus was isolated were asymptomatic. Virus cultures from asymptomatic
persons required longer incubation time than those from symptomatic
persons to become positive (12.7 vs. 8.7 days, p<0.007), suggesting
low titers of virus in these specimens. The study design did not
permit assessment of whether asymptomatic persons transmitted influenza.
|
Asymptomatic shedding at a low titer may be common
during a seasonal outbreak.
|
| |
|
Murphy (5)
|
In the control arm of a study, 7 adult volunteers
were nasally infected with wild-type H3N2 virus
|
Peak virus shedding occurred 2 days after nasal
inoculation, and shedding ceased by day 6. Titer of virus shed and
daily fever score (reflects height and duration of fever) were strongly
correlated (p<0.001). 1/7 study participants had mild symptoms
without fever and shed less virus.
|
Fever score and quantity of virus shed were strongly
correlated.
|
| |
|
Couch (6)
|
In a vaccine study, 29 adults received vaccines,
and 11 controls received saline. All were nasally infected with
H3N2
|
The vaccinated group had a reduced rate and severity
of illness. Among controls (without specific antibody), titer of
virus shed and daily severity of illness scores (p<0.001) were
strongly correlated. In the combined group, peak viral shedding
occurred 3 days after infection. Virus was shed a mean of 5.7 days.
6/29 vaccine recipients and 5/11 controls shed low levels of virus
but did not become ill.
|
Severity of illness and quantity of virus shed were
strongly correlated; a substantial rate of asymptomatic shedding
occurred at low titer.
|
| |
|
Khakpour (7)
|
Daily cultures of 29 adult prisoners after natural
exposure to influenza, Iran,
1968
|
Virus was isolated from 5/29 contacts. One person
had influenza isolated from a throat washing and blood, which is
rare, 12 h before symptoms. Four persons had virus isolated from
throat washings but never had symptoms; acute antibody titer was
high in 2. Virus titrations were not performed.
|
Presymptomatic and asymptomatic shedding can occur.
|
| |
|
Philip (8)
|
Surveillance in families, Washington,
DC area, 1952–1955
|
In households with proven influenza illness, influenza
A was isolated from 8 (38%) of 21 contacts with acute afebrile respiratory
illness and 2 (5%) of 40 healthy contacts. Influenza B virus was
isolated from 2 (11%) of 19 contacts with acute afebrile respiratory
illness and 0 of 47 contacts. Age distribution of culture-positive
contacts was not reported.
|
Symptomatic household contacts commonly shed influenza
A virus. Asymptomatic shedding of influenza A and B viruses was
uncommon.
|
| |
|
Monto (9)
|
Surveillance in families, Tecumseh, Michigan, 1976–1981
|
During seasonal epidemics among persons with serologically
proven influenza A (H3N2) infection, at least 15%–25% were ill.
Among persons with serologically proven influenza B, at least 19%–34%
were ill. Among persons with febrile respiratory illness, influenza
virus was isolated from 19.7%.
|
≈60% of seasonal infections were asymptomatic.
(This includes persons with partial immunity due to infection with
the same subtype as in previous years; the percentage of asymptomatic
infections would be lower in a pandemic.) Viral shedding in asymptomatic
persons is likely to be quite low.
|
| |
|
Hayden (10)
|
19 volunteers infected with influenza A H1N1
|
All study participants were symptomatic, and symptom
scores peaked on day 2 and returned to normal by day 8. Virus titers
correlated with symptoms.
|
Viral shedding was correlated with symptoms.
|
|
References
- Frank AL, Taber LH, Wells CR, Wells JM, Glezen WP,
Paredes A. Patterns
of shedding of myxoviruses and paramyxoviruses in children. J Infect
Dis. 1981;144:433–41.
- Hall CB, Dolin R, Gala CL, Markovitz DM, Zhang YQ, Madore PH, et al.
Children
with influenza A infection: treatment with rimantadine. Pediatrics.
1987;80:275–82.
- Davis DJ, Philip RN, Bell JA, Vogel JE, Jensen DV. Epidemiologic
studies on influenza in familial and general population groups. 1951–1956.
III. Laboratory observations. Am J Hyg. 1961;73:138–47.
- Foy HM, Cooney MK, Allan ID, Albrecht JK. Influenza
B in households: virus shedding without symptoms or antibody response.
Am J Epidemiol. 1987;126:506–15.
- Murphy BR, Chalhub EG, Nusinoff SR, Kasel J, Chanock RM. Temperature-sensitive
mutants of influenza virus. 3. Further characterization of the ts-1(E)
influenza A recombinant (H3N2) virus in man. J Infect Dis. 1973;128:479–87.
- Couch RB, Douglas RG Jr, Fedson DS, Kasel JA. Correlated
studies of a recombinant influenza-virus vaccine. 3. Protection against
experimental influenza in man. J Infect Dis. 1971;124:473–80.
- Khakpour M, Saidi A, Naficy K. Proved
viraemia in Asian influenza (Hong Kong variant) during incubation period.
BMJ. 1969;4:208–9.
- Philip RN, Bell JA, Davis DJ, Beem MO, Beigelman PM, Engler JI, et
al. Epidemiologic
studies on influenza in familial and general population groups, 1951–1956.
II. Characteristics of occurrence. Am J Hyg. 1961;73:123–37.
- Monto AS, Koopman JS, Longini IM Jr. Tecumseh
study of illness. XIII. Influenza infection and disease, 1976–1981.
Am J Epidemiol. 1985;121:811–22.
- Hayden FG, Fritz R, Lobo MC, Alvord W, Strober W, Straus SE. Local
and systemic cytokine responses during experimental human influenza
A virus infection. Relation to symptom formation and host defense.
J Clin Invest. 1998;101:643–9.
1The writing group was established by request
of the WHO Global Influenza Programme.
It consisted of the following persons: David Bell,
Centers for Disease Control and Prevention, Atlanta, Georgia, USA (coordinator);
Angus Nicoll, European Centre for Disease Prevention and Control, Stockholm,
Sweden, and Health Protection Agency, London, United Kingdom (working
group chair); Keiji Fukuda, WHO, Geneva, Switzerland; Peter Horby, WHO,
Hanoi, Vietnam; and Arnold Monto, University of Michigan, Ann Arbor, Michigan,
USA. The following persons made substantial contributions: Frederick Hayden,
University of Virginia, Charlottesville, Virginia, USA; Clare Wylks and
Lance Sanders, Australian Government Department of Health and Ageing,
Canberra, Australian Capital Territory, Australia; and Jonathan Van Tam,
Health Protection Agency, London, United Kingdom.
|